Table 1.
Demographics and clinical characteristics of the study cohort.
Fig 1.
Biomarker profiles over the course of the liver event:
a) microRNA122-5p (miRNA122); b) Alanine aminotransferase (ALT); c) Aspartate aminotransferase (AST); d) Total bilirubin (TBL). The visits were: visit 1 (day 1, recognition); visit 2 (day 7); and visit 3 (≥30 days after recognition of the acute episode).
Fig 2.
Spearman’s correlation analysis:
a) microRNA-122-5p (miRNA122) vs. Alanine Aminotransferase (ALT); b) miRNA122 vs. Aspartate Aminotransferase (AST); c) miRNA122 vs. Total Bilirubin (TBL). Abbreviation: xULN, times the upper limit of normal. Values below the lower limit of quantification (LLOQ) were not included in the analysis.